Ceftaroline fosamil: Drug profile and clinical data

Future Microbiology

Volumn 6, Issue 1, 2011, Pages 9-18

  Kanafani, Zeina A ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

lactams; ceftaroline; cephalosporin; methicillin resistance; Staphylococcus aureus

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; AZTREONAM; BETA LACTAM ANTIBIOTIC; CEFEPIME; CEFTAROLINE FOSAMIL; CEFTRIAXONE; DAPTOMYCIN; IMIPENEM; LEVOFLOXACIN; LINEZOLID; MEROPENEM; NXL 104; TAZOBACTAM; TEICOPLANIN; TIGECYCLINE; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; COMMUNITY ACQUIRED PNEUMONIA; DIARRHEA; DRUG BINDING; DRUG HALF LIFE; DRUG INHIBITION; DRUG MECHANISM; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; ENDOCARDITIS; ENTEROCOCCUS FAECALIS; HEADACHE; HUMAN; INFECTION; INJECTION SITE REACTION; INSOMNIA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MORGANELLA MORGANII; NAUSEA; NONHUMAN; OSTEOMYELITIS; PERITONITIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RASH; SIDE EFFECT; SKIN INFECTION; STAPHYLOCOCCUS INFECTION; URINE COLOR;

ANIMALS; ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; CEPHALOSPORINS; CLINICAL TRIALS AS TOPIC; COMMUNITY-ACQUIRED INFECTIONS; DRUG RESISTANCE, BACTERIAL; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; MICE; MICROBIAL SENSITIVITY TESTS; PNEUMONIA, BACTERIAL; RABBITS; SKIN DISEASES, BACTERIAL;

BACTERIA (MICROORGANISMS); METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NEGIBACTERIA; POSIBACTERIA; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

EID: 78650464271     PISSN: 17460913     EISSN: None     Source Type: Journal    
DOI: 10.2217/fmb.10.132     Document Type: Article

References (34)

1. Kanafani ZA, Fowler VG Jr: [Staphylococcus aureus infections: new challenges from an old pathogen]. Enferm. Infecc. Microbiol. Clin. 24(3), 182-193 (2006).
2. Stryjewski ME, Corey GR: New treatments for methicillin-resistant Staphylococcus aureus. Curr. Opin. Crit. Care 15(5), 403-412 (2009).
3. Corey GR, Wilcox M, Talbot GH et al.: Integrated analysis of CANVAS 1 and 2: Phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin. Infect. Dis. 51(6), 641-650 (2010).
4. Talbot GH, Thye D, Das A, Ge Y: Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections. Antimicrob. Agents Chemother. 51(10), 3612-3616 (2007).
5. Eckburg P, Friedland HD, Lee J, Llorens L, Critchley IA, Thye D: FOCUS 1 and 2: randomized, double-blinded, multicenter Phase 3 trials of the efficacy and safety of ceftaroline (CPT) vs ceftriaxone (CRO) in community-acquired pneumonia (CAP). 49th Interscience Conference on Antimicrobial Agents and Chemotherapy San Francisco, CA, USA, 12-15 September 2009 (Abstract L1-345a).
6. Ishikawa T, Matsunaga N, Tawada H et al.: TAK-599, a novel N-phosphono type prodrug of anti-MRSA cephalosporin T-91825: synthesis, physicochemical and pharmacological properties. Bioorg. Med. Chem. 11(11), 2427-2437 (2003).
7. Villegas-Estrada A, Lee M, Hesek D, Vakulenko SB, Mobashery S: Co-opting the cell wall in fighting methicillin-resistant Staphylococcus aureus: potent inhibition of PBP 2a by two anti-MRSA b-lactam antibiotics. J. Am. Chem. Soc. 130(29), 9212-9213 (2008).
8. Moisan H, Pruneau M, Malouin F: Binding of ceftaroline to penicillin-binding proteins of Staphylococcus aureus and Streptococcus pneumoniae. J. Antimicrob. Chemother. 65(4), 713-716 (2010).
9. Brown SD, Traczewski MM: In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing. Antimicrob. Agents Chemother. 53(3), 1271-1274 (2009).
10. Fenoll A, Aguilar L, Robledo O et al.: In vitro activity of ceftaroline against Streptococcus pneumoniae isolates exhibiting resistance to penicillin, amoxicillin, and cefotaxime. Antimicrob. Agents Chemother. 52(11), 4209-4210 (2008).
11. Ge Y, Biek D, Talbot GH, Sahm DF: In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. Antimicrob. Agents Chemother. 52(9), 3398-3407 (2008).
12. Sader HS, Fritsche TR, Jones RN: Antimicrobial activities of ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 52(3), 1153-1155 (2008).
13. Sader HS, Fritsche TR, Kaniga K, Ge Y, Jones RN: Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains. Antimicrob. Agents Chemother. 49(8), 3501-3512 (2005).
14. Saravolatz L, Pawlak J, Johnson L: In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates. Antimicrob. Agents Chemother. 54(7), 3027-3030 (2010).
15. Vidaillac C, Leonard SN, Rybak MJ: In vitro activity of ceftaroline against methicillin-resistant Staphylococcus aureus and heterogeneous vancomycin-intermediate S. aureus in a hollow fiber model. Antimicrob. Agents Chemother. 53(11), 4712-4717 (2009).
16. Farrell DJ, Moet GJ, Rhomberg PR, Sader HS, Jones RN: Activity of ceftaroline against recent (2009) and multidrug-resistant Streptococcus pneumoniae isolates from Europe and the United States. Clin. Microbiol. Infect. 16(S2), S557 (2010).
17. Jacobs MR, Good CE, Windau AR et al.: Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States. Antimicrob. Agents Chemother. 54(6), 2716-2719 (2010).
18. Jacqueline C, Caillon J, Le Mabecque V et al.: In vivo activity of a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, ceftaroline, against vancomycin-susceptible and -resistant Enterococcus faecalis strains in a rabbit endocarditis model: a comparative study with linezolid and vancomycin. Antimicrob. Agents Chemother. 53(12), 5300-5302 (2009).
19. Mushtaq S, Warner M, Ge Y, Kaniga K, Livermore DM: In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes. J. Antimicrob. Chemother. 60(2), 300-311 (2007).
20. Vidaillac C, Leonard SN, Sader HS, Jones RN, Rybak MJ: In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant Gram-negative pathogens, including b-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 53(6), 2360-2366 (2009).
21. Mushtaq S, Warner M, Williams G, Critchley I, Livermore DM: Activity of chequerboard combinations of ceftaroline and NXL104 versus b-lactamase-producing Enterobacteriaceae. J. Antimicrob. Chemother. 65(7), 1428-1432 (2010).
22. Citron DM, Tyrrell KL, Merriam CV, Goldstein EJ: In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria. Antimicrob. Agents Chemother. 54(4), 1627-1632 (2010).
23. Mushtaq S, Livermore DM: AmpC induction by ceftaroline. J. Antimicrob. Chemother. 65(3), 586-588 (2010).
24. Andes D, Craig WA: Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target. Antimicrob. Agents Chemother. 50(4), 1376-1383 (2006).
25. Pankuch GA, Appelbaum PC: Postantibiotic effect of ceftaroline against Gram-positive organisms. Antimicrob. Agents Chemother. 53(10), 4537-4539 (2009).
26. Ge Y, Hubbel A: In vitro evaluation of plasma protein binding and metabolic stability of ceftaroline (PPI-0903M). Presented at: 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 27-30 September 2006.
27. Ge Y, Redman R, Floren L, Liao S, Wikler M: Single-dose phamacokinetics of ceftaroline (PPI-0903) in healthy subjects. Presented at: 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 27-30 September 2006.
28. Ge Y, Redman R, Floren L, Liao S, Wikler M: The pharmacokinetics (PK) and safety of ceftaroline (PPI-0903) in healthy subjects receiving multiple-dose intravenous (IV) infusions. Presented at: 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 27-30 September 2006.
29. Jacqueline C, Caillon J, Miegeville AF: Penetration of ceftaroline (PPI-0903), a new cephalosporin, into lung tissues: measurement of plasma and lung tissue concentrations after a short IV infusion in the rabbit. Presented at: 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 27-30 September 2006.
30. Iizawa Y, Nagai J, Ishikawa T et al.: In vitro antimicrobial activity of T-91825, a novel anti-MRSA cephalosporin, and in vivo anti-MRSA activity of its prodrug, TAK-599. J. Infect. Chemother. 10(3), 146-156 (2004).
31. Jacqueline C, Caillon J, Le Mabecque V et al.: In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin- intermediate Staphylococcus aureus in a rabbit endocarditis model. Antimicrob. Agents Chemother. 51(9), 3397-3400 (2007).
32. Jacqueline C, Amador G, Caillon J et al.: Efficacy of the new cephalosporin ceftaroline in the treatment of experimental methicillin-resistant Staphylococcus aureus acute osteomyelitis. J. Antimicrob. Chemother. 65(8), 1749-1752 (2010).
33. Xiong YQ, Li Y, Abdelsayed GA, Biek D, Bayer AS: Real-time evaluation of ceftaroline, a new cephalosporin, versus vancomycin and daptomycin in a rat S. aureus endocarditis model using in vivo bioluminescent imaging. Presented at: 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA, 17-20 September 2007.
34. Panagiotidis G, Backstrom T, Asker- Hagelberg C, Jandourek A, Weintraub A, Nord CE: Effect of ceftaroline on normal human intestinal microflora. Antimicrob. Agents Chemother. 54(5), 1811-1814 (2010).